Compare EIX & WST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EIX | WST |
|---|---|---|
| Founded | 1886 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Medical/Dental Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.8B | 25.8B |
| IPO Year | 1994 | 2004 |
| Metric | EIX | WST |
|---|---|---|
| Price | $76.51 | $358.36 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 13 | 7 |
| Target Price | $72.09 | ★ $325.86 |
| AVG Volume (30 Days) | ★ 2.0M | 682.3K |
| Earning Date | 04-28-2026 | 04-23-2026 |
| Dividend Yield | ★ 5.17% | 0.30% |
| EPS Growth | ★ 248.94 | 1.49 |
| EPS | 1.37 | ★ 1.92 |
| Revenue | ★ $19,317,000,000.00 | $2,886,900,000.00 |
| Revenue This Year | N/A | $6.76 |
| Revenue Next Year | $3.17 | $6.22 |
| P/E Ratio | ★ $55.82 | $186.74 |
| Revenue Growth | ★ 9.76 | 1.95 |
| 52 Week Low | $50.58 | $206.80 |
| 52 Week High | $77.95 | $367.66 |
| Indicator | EIX | WST |
|---|---|---|
| Relative Strength Index (RSI) | 62.64 | 63.86 |
| Support Level | $68.62 | $349.41 |
| Resistance Level | N/A | $367.66 |
| Average True Range (ATR) | 1.48 | 7.68 |
| MACD | 0.10 | -0.95 |
| Stochastic Oscillator | 69.75 | 62.74 |
Edison International is the parent company of Southern California Edison, an electric utility that distributes electricity to 5 million customers in a 50,000-square-mile area of Southern California, excluding Los Angeles. Edison Energy owns interests in nonutility businesses that deal in energy-related products and services. In 2014, Edison International sold its wholesale power generation subsidiary Edison Mission Energy out of bankruptcy to NRG Energy.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.